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Objectives. This study forms part of a clinical survey of 
problems in the optimal management of patients with 
inherited neuromuscular diseases seen at Kalafong Hospital 
in Pretoria. Our objectives were to determine the problems 
associated with providing patients with optimal 
management until true remission (cure), and to apply the 
findings to ongoing improvement of optimal management. 
This is the first report of the series. 
Methods. Twenty-six patients were studied prospectively 
from 1986to1998. Early sternal-splitting thymectomy on 
class II -V patients as well as anticholinesterases, 
corticosteroids, azathioprine, plasma exchange, intensive 
care and various combinations of these constituted part of 
the optimal management. An assessment of the total 
monthly income and distance from hospital was done for 
each patient. 
Results. Five of the 15 thymectomised patients (33.3%) were 
lost to follow-up after reaching remission. Of the remaining 
10 patients, 6 (40%) are in true remission and the remaining 
4 (26.7%) are in pharmacological remission. Four of the 11 
patients (36%) treated non-surgically were lost to follow-up. 
Of the remaining patients, 1 (9.1 % ) is in true remission and 
the remaining 6 (54.5%) are in pharmacological remission. 
The average monthly income of patients lost to follow-up 
in the thymectomised group was lower than that of patients 
who continued follow-up, and their homes were further 
away from hospital. In the non-surgical group the average 
monthly income of patients lost to follow-up was higher 
than that of patients who continued follow-up and their 
homes were nearer to the hospital. 
Conclusion. Early thymectomy (the aggressive approach) 
resulted in 40% cures, 26.7% pharmacological remissions, 
no mortality, minimal morbidity, and early discharge. Loss 
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to follow-up was one of the biggest problems in providing 
optimal management for these patients.We modified optimal 
management in response to our patients' concerns without 
sacrificing excellence, and found that poverty and poor access 
to tertiary hospitals were possible contributory factors to loss 
to follow-up. Suggestions are made with regard to tackling the 
problems. 
Myasthenia gravis (MG) is a disorder of neuromuscular 
function resulting from an immunologically based premature 
destruction of acetylcholine receptors. 
S Afr Med J 2002; 92: 225-230. 
Myasthenia gravis (MG) is a disorder of neuromuscular 
function resulting from an immunologically based premature 
destruction of acetylcholine receptors.' 
Although Mendelian genetics does not seem important in the 
aetiology of MG, there is increasing evidence that susceptibility 
genes do play a role and that what is inherited is a genetic 
predisposition.2 In addition, the genetic contribution to MG 
susceptibility is significant, with a 36% concordance in 
monozygotic twins3 and a family history of the disease in 2 -
3% of all patients.• There are hereditary forms of MG as well. 
For the abovementioned reasons as well as for the sake of 
continuity in covering disorders from the anterior horn 
cells/cranial nerve nuclei to skeletal muscles, MG patients 
were included in the survey. Treatment of the MG patient is 
generally lifelong, extending into all areas of his or her activity.5 
The goal of MG therapy is to produce normal function, with 
rapid onset of the effect.6 Although the number of therapeutic 
options available has increased greatly over the past three 
decades, experts in the field continue to debate over the most 
successful therapeutic approach. It has been stated that the art 
of providing safe care for patients with myasthenia gravis lies 
in deciding when to treat and when not to treat aggressively.' 
A number of factors influence the decision on the mode of 
therapy to use, namely: 
1. The rate of progression, which along with the severity and 
distribution of the weakness, is the most important 
consideration for immediate therapeutic decisions. 
2. Clinical considerations, including resources available or 
ability to comply with a therapeutic strategy. At Kalafong 
Hospital we were faced with a unique set of circumstances that 
influenced our choice of man~gem~_nt, i.e.: (i) limited resources l:T:'r.I 
from the national health services; (u) 14 (93.3%) of the 15 ~ 
patients who underwent thymectomy were either employed 
and contributing to the family income or were in the age group 
in which they should have been doing so - they were all 
unwilling to spend many months in hospital and we 
anticipated that follow-up would be unreliable in some of 
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them; (iii) all our patients were from the poorest section of the 
South African population; and (iv) a significant correlation had 
been found between the brevity of the interval between the 
onset of MG and thymectomy, and the likelihood of a good 
response to the operation.' 
Because of the abovementioned factors our management 
protocol had to aim for the shortest possible stay in hospital. 
This dictated that we adopt an aggressive approach to 
management of generalised MG in an attempt to meet our 
patients' expectations, with the resources at our disposal. These 
circumstances led us to embark on the present study. 
OBJECTIVES 
The objectives of the present study form part of a prospective 
clinical survey of problems in the optimal management of 
patients with inherited neuromuscular disorders seen at 
Kalafong Hospital. 
Our objectives were: (i) to determine, prospectively, the 
problems associated with providing optimal management to 
these patients; (ii) to assess the effectiveness of optimal 
management, in other words to attempt to answer the question 
'Are we providing effective care to MG patients in our region, 
and are they appearing to benefit from it?' - this was especially 
with regard to the favourable outcome of early thymectomy in 
generalised MG reflected in the literature; (iii) to apply the 
experience obtained to ongoing improvement of optimal 
management; and (iv) ultimately to devise appropriate, cost-
effective, evidence-based guidelines to manage these patients. 
MATERIALS AND METHODS 
Twenty-six consecutive MG patients were studied prospectively 
from 1986 to 1998. Patients were admitted to the study if 
they satisfied the following two minimum inclusion criteria: 
(i) if they showed typical clinical features of MG; and (ii) if one 
of the following supportive tests was positive: (a) the 
intravenous (IV) edrophonium test or intramuscular (IM) 
atrophine/neostigmine test, (b) the decremental response to 
repetitive nerve stimulation test,'(c) the response to 
anticholinesterase medication,' and (d) the serum aceylcholine 
receptor antibody test.10 
The following were recorded for each patient: (i) total 
monthly income, and the total number of people per household 
that the income had to support; and 
(ii) the distance between each patient's home and the hospital 
(justification for including these two parameters will be given 
in the discussion section). 
In addition to the above tests, the following laboratory tests 
were done on each patient: antinuclear factor, thyroid function 
tests, auto-antibodies to the thyroid gland, rheumatoid factor, 
full blood count with differential count and erythrocyte 
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sedimentation rate, antistriated muscle antibodies, creatine 
phosphokinase, and chest radiographs. Serum anti-
acetylcholine receptor antibodies were measured in some of the 
patients. A computed tomography (CT) scan of the superior 
mediastinum was also done on all patients to assess thymus 
size. 
The agressive management of generalised MG (classes Il-V) 
consisted of restoration of normal strength using high-dose 
daily or alternate-day corticosteroids orally or parenterally, 
equivalent to 50 -100 mg prednisone,11 and early thymectomy 
(within a year of diagnosis).12 
Long-term follow-up until true remission (cure) was carried 
out on all the patients. 
CLASSIFICATION 
The patients were then classified according to the Modified 
Osserman Classification as used at the University of Virginia 
(Table I).13 
Table I. Classification of disease severity 
Class Description Distribution 








Mild generalised weakness, usually with 
ocular muscle weakness 
Predominantly oroph<iryngeal involvement, 
usually with mild generalised weakness 
Moderate generalised weakness 
Severe generalised weakness (crisis) 
The aggressive management of generalised MG consisted of: 
1. Restoration of normal strength using high-dose daily (50 -
100 mg) or alternate-day corticosteroids orally or parenterally11 
(Table II). For various reasons restoration of normal strength 
using high-dose corticosteroids was achieved in only 7 patieµts 
who underwent thymectomy. In the remaining 8 patients who 
underwent thymectomy restoration of strength was initiated 
using lower doses of corticosteroids, or pyridostigmine 
bromide. 
2. Following thymectomy the patients were kept on doses of 
corticosteroids and/ or azathioprine sufficient to maintain 
normal strength. Small reductions in dose of corticosteroids, 
namely 5 - 10 mg, were effected at the end of eyery month until 
true remission, that is normal strength while off all medications 
for a period of at least 2 years, was reached.14 The minimum 
maintenance dose varied and was established by trial and error 
for each patient who deteriorated on lower doses. 
3. Anticholinesterase medication was used as supplementary 
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Table II. Treatment with corticosteroids and anticholinesterase 
drugs 
Initial doses of corticosteroids Route of 
Patient Class daily or on alternate days (A/D) administration 
Prednisone 60 mg/ day Oral 
2 I Pyridostigmine Oral 
3 I Pyridostigmine Oral 
4 Pyridostigmine Oral 
5 Prednisone 10 mg AID 
and pyridostigmine Oral 
6 Pyridostigmine Oral 
7 II Prednisone 20 mg/ day Oral 
8 II Pyridostigmine Oral 
9 II No treatment given 
10 II Pyridostigmine Oral 
11 II Pyridostigmine Oral 
(Surgical treatment group) 
12 II Pyridostigmine Oral 
13 II Pyridostigmine Oral 
14 III Prednisone 100 mg AID Oral 
15 III Pyridostigmine Oral 
16 IV Prednisone 55 mg/ day Oral 
17 IV Prednisone 60 mg/ day Oral 
18 IV Prednisone 35 mg A/D Oral 
19 IV Prednisone 10 mg/ day Oral 
20 IV Pyridostigmine 60 mg/ day Oral 
21 N Prednisone 30 mg A/D Oral 
22 v Prednisone 60 mg/ day Oral 
23 v Prednisone 60 mg/day Oral 
24 v Prednisone 60 mg/ day Oral 
25 v Decadron 10 mg IV 4 times a day Intravenous 
26 v Prednisone 40 mg/day Oral 
treatment as required by the patient. The doses of 
pyridostigmine used ranged from 60 mg three times a day to 
60 mg five times a day orally. 
4. Patients were also treated with isoniazid (INH) as 
prophylaxis against tuberculosis, as well as with potassium 
and calcium supplements. Oral cimetidine was used as 
prophylaxis against peptic ulceration. 
5. Azathioprine (Imuran) was given orally at a dose of 
2 mg/kg of body weight to replace or reduce corticosteroids in 
those patients requiring high doses of corticosteroids to 
maintain normal strength. This was to reduce the likelihood of 
complications from high-dose corticosteroids over a prolonged 
period. The dose of corticosteroids was then slowly reduced, 
and if at all possible, stopped. 
TIME INTERVAL BETWEEN ADMISSION AND 
THYMECTOMY 
The time interval between admission and thymectomy ranged 
from 2 weeks to 1 year and 3 months, with an average of 
3.05 months. The only exception was patient number 20 in 
class IV, a member of our hospital staff, who eventually 
underwent thymectomy 2.5 years after diagnosis when she 
started becoming hypertensive as a result of the corticosteroid 
treatment. The average of 3.05 months was well within our 
guideline of 1 year. 
RESULTS 
Confirmatory tests - edrophonium chloride tests 
The edrophonium chloride test (also known as the Tensilon 
test) or the atropine-neostigmine tests were positive in all 
patients. The repetitive nerve stimulation at 2 Hz test was 
positive in all the patients in whom it was done (except for one 
(class 1) patient, in whom it was negative. Single-fibre 
electromyography was positive in 1 of 2 patients in class I. 
Thymic histology 
Histological examination of the thymus gland showed thymitis 
in 10 patients, thymoma in 2 patients and was normal in the 
remaining 3 patients. 
Serum anti-acetylcholine receptor antibodies 
Serum anti-acetylcholine receptor antibodies, done in 9 
patients, were positive in 5 patients (38.5%) and negative in 4 
(44.4%). 
Additional tests 
Two patients had primary thyrotoxicosis on thyroid function 
testing. The remaining tests were normal. 
Results of treatment 
Classification of treatment results 
We modified Pascuzzi and Johns's13 classification of treatment 
results as follows: (i) unimproved: absence of objective 
improvement; (ii) moderate improvement: objective 
improvement but functionally limited by weakness; 
(iii) marked improvement: without significant symptoms and 
return to ordinary activities of daily living, but with slight 
weakness on examinatio,n; (iv) pharmacological remission: 
asymptomatic on treatment with no weakness on examination, 
but weakness of eye-closure allowed; (v) remission: 
asymptomatic off all treatment with no weakness on 
examination, for a period of less than 2 years; and (vi) true 
remission (cured): asymptomatic without treatment for a 
period of at least 2 years.14 
Rei;!ults of classes I and II patients treated without 
thymectomy 
Four of the 11 patients (36%) were lost to follow-up. Of the 
remaining 7 patients who continued follow-up, 1 (9.1 %) 
reached true remission (cure) and the rest are in 
pharmacological remission. 
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The average monthly income, per person, of patiei:its l_ost to 
follow-up was R29.40, and their average distance from hospital 
was 72 km. On the other hand, the average monthly income of 
patients still on follow-up was R18.50, and their average 
distance from hospital was 157 km. 
Results of classes II - V patients who underwent 
thymectomy 
Of the 15 patients who underwent sternal-splitting 
thymectomy, 5 (33.3%) were lost to follow-up. Six of the post-
thymectomy patients (40%) still on follow-up are in true 
remission (cured) and the rest are in pharmacological 
remission. The 40% true remissions (cures) and the 26.7% 
remissions means that 66.7% of the patients went back to their 
normal lives. All the patients in true remission were female and 
aged 35 years and younger. 
Histological examination of the thymus gland showed 
thymitis in 4 patients and was normal in the other 2 patients. 
The duration of disease before treatment ranged from 3 months 
to 7 years, with an average of 2 years and 4 months. The period 
from thymectomy to remission in this group ranged from 5 
months to 9 years, with an average of 2 years and 2 months. 
The time interval between admission and thymectomy 
(classes II - V patients) in the 7 patients who achieved 
restoration to normal strength with high-dose corticosteroids 
averaged 4.5 months and ranged from 0.75 months to 1 year 
and 3 months. In the other 5 patients who received lower doses 
of corticosteroids for induction the time interval averaged 
1.32 months and ranged from 0.5 months to 2.32 months. 
DISCUSSION 
The 100% positivity of edrophonium chloride (Tensilon test) or 
the atropine-neostigmine tests is in agreement with reports in 
the literature of high (88%) yield for the test. 10 The test was 
done in only 2 of the patients who were 'cured' following 
thymectomy, with 1 positive and 1 negative. These tests, even 
with the availability in recent years of the acetylcholine 
receptor antibody titre and single-fibre electromyography, have 
remained the gold standard for the diagnosis of MG.10 
The serum anti-acetylcholine receptor antibodies done in 9 
patients were positive in 5 patients (55.6%) and negative in 4 
patients (44.4%). 
The distribution of positives according to class was 2 
patients out of 4 (50%) in class II, 1 out of 3 (33.33%) in class IV, 
and 1 each (100%) in classes III and V. 
The test was done in only 2 of the patients who were 'cured' 
following thymectomy, with 1 positive and 1 negative. The 
numbers are too small to address the question; raised by 
Mossmann et al,15 namely whether thymectomy constitutes 
appropriate management for the group of anti-acetylcholine-
negative patients. 
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Untreated, there is a 40% mortality rate over 10 years for 
MG.16 
The immediate and short-term goal of therapy is to produce 
normal function of weak muscles rapidly. As the disorder of 
neuromuscular function results from premature destruction of 
acetylcholine receptors by antibodies, therapy aims at 
preventing or slowing down synthesis of these acetylcholine 
receptor antibodies.1'The ultimate goal of therapy in MG is a 
cure. 
There is general agreement on four principles of therapy, 
namely:1' (i) anticholinesterase drugs are useful in all clinical 
forms of MG; (ii) they are the mainstay of treatment in ocular 
MG; (iii) plasmapheresis confers only transient improvement; 
and (iv) the presence of thymoma is an absolute indication for 
thymectomy. 
Six of our post-thymectomy patients (40%) still on follow-up 
are in true remission (cured) and the rest are in 
pharmacological remission. This means that 100% of the post-
thymectomy patients who continued follow-up returned to 
normal life. The results of the aggressive approach to 
management of generalised MG show that our optimum 
management is effective and beneficial to our patients. 
The 40% true remission (cures) and 26.7% remission means 
that 66.7% of the patients went back to their normal lives. This, 
together with the zero mortality and minimal morbidity, 
compares with the best results in the world literature.7-1' 
Thymectomy is generally accepted as being effective in 66 -
86% of patients in whom there is no thymoma20 and Lindberg et 
al.21 have also stated that the probability of long-term 
spontaneous remission after thymectomy is about 50%. 
One aspect of our aggressive approach, namely restoration of 
normal strength using high-dose corticosteroids, was achieved 
in only 7 of the 15 patients who underwent thymectomy. The 
main reason is that some of the patients had already been 
started on treatment before referral. The 4.5-month time 
interval between admission and thymectomy in this group is 
longer than the 1.32-month average time interval for the group 
that received lower doses of corticosteroids. Unfortunately the 
time interval is not an accurate reflection of the speed of 
achieving normal strength as for personal reasons there were 
delays to thymectomy in some of the patients when the patient 
was in a state of marked improvement or normal strength. 
However, in almost the whole group thymectomy was 
performed within a year of diagnosis. 
The advantages of our aggressive approach include: (i) rapid 
induction of marked improvement or remission in a high 
percentage of MG patients within a predictable time period;-
( ii) markedly reduced morbidity at thymectomy, usually 
performed approximately 3 months after commencement of 
prednisone treatment, and when the patient was in a state of 
marked improvement or remission; and (iii) early return to 
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normal activities of daily living, with outpatient management.22 
The one potentially dangerous disadvantage of the 
aggressive approach is the occurrence of exacerbations early in 
therapy. This occurred in 1 (6.7%) of our 15 patients. Our policy 
is that all patients have to be in hospital during this period in 
order to monitor and treat this complication. 
Some researchers have suggested that beginning therapy 
with low-dose alternate-day steroid treatment with gradual 
increase in dosage may reduce the frequency of early 
exacerbations." However, according to other authors21 that 
regimen does not eliminate the risk of exacerbation, and had 
the potential disadvantages of prolonged time in achieving 
improvement and fluctuating strength on an alternate-day 
basis.22 
All our patients in true remission were females 35 years old 
and younger. Histological examination of their thymus glands 
showed hyperplasia in 4 and normal thymus in 2. Thymectomy 
was performed early in 5 and late in 1 patient. Several recent 
studies concur that thymectomy in generalised MG patients 
hastens the onset and increases the frequency of remission and 
that most remissions occur in young women with hyperplastic 
glands and high antibody titres.2" 25 
Other researchers further state that thymectomy done early, 
i.e. during the first year of disease, seems to improve outcome 
significantly.26 In contrast, Grob and colleagues27 believe that 
thymectomy should be limited to more seriously ill patients. 
The rationale behind thymectomy remains unknown. 
Thymic lymphocytes from over 70% of patients with MG and 
thymitis spontaneously synthesise antibodies against the 
acetylcholine receptors in vitro, suggesting that they are already 
primed and that in vivo antibody production takes place in the 
thymus.20 
Plasmapheresis leads to transient reduction of serum anti-
acetylcholine receptor antibody levels, while thymectomy and 
corticosteroids lead to longer-lasting reduction. 
The 9.1 % true remission (cure) rate in the class I and II 
patients treated without thymectomy compares well with the 
spontaneous cure rate of 10% reported in the literature.12 
Results for this group of patients cannot be compared with 
those of the thymectomised patients as they are not strictly 
comparable in terms of disease severity (class). 
The total monthly income per household of thymectomised 
. patients ranged from R40 to Rl 200. According to the 
Department of Social Welfare's means test (M Steenkamp-
unpublished data, 1998), if the household income is below 
R800 per month, then the child qualifies for a child support 
grant. Eleven of the 15 patients in this group (73%) had 
household incomes below R800. Our project therefore turned 
out to be one of finding out whether loss to follow-up would 
be higher among the poorest of the poor living furthest from 
tertiary hospitals. This fact was confirmed by our results in the 
surgical (thymectomy) group where the average distance from 
hospital of patients lost to follow-up was greater and their 
average monthly income per household lower than those of 
patients who continued follow-up. 
The total monthly income per household of patients treated 
without thymectomy ranged from R50 to Rl 200. Nine of the 11 
patients (82%) had monthly incomes below R800 per month. 
The finding in the surgical (thymectomy) group with regard to 
loss to follow-up being related to the lowest income and 
furthest distance from hospital was not confirmed. Some of the 
patients had higher incomes and lived nearer hospital than 
those who continued follow-up. This suggests that there are 
reasons for loss to follow-up other than poverty and long 
distances from hospital.° However, what was confirmed in this 
group was that the majority of patients fell into the poor group 
according to the Department of Social Welfare's means test. In 
addition, it was also found that most of the patients lived long 
distances from tertiary hospitals. 
In choosing household income and distance from hospital 
we were using common sense to assess the means of our 
patients with the resources available to us. How valid are these 
two parameters as a means test? It is reassuring and gratifying 
to see that the Gauteng Provincial Government, Department of 
Welfare and Population Development: Social Security uses the 
same two parameters plus the type of dwelling as a simple test 
for a child-support grant. Furthermore, according to their 
calculations this simple means test was so accurate that it 
enabled them to identify 99% of children from the poorest 
households in South Africa (M Steenkamp - unpublished 
data, 1998). 
The results of the patients who continued follow-up are 
promising with regard to the outcome of our aggressive 
approach, but they are hampered by the percentage of patients 
lost to follow-up (up to 36% of our patients). 
It is government policy to improve the social circumstances 
of all South African citizens, especially the circumstances of the 
poor. It is also government policy to bring health services to 
within reasonable reach of all citizens, in particular those living 
in rural areas. These are medium- to long-term measures. Until 
this ideal situation is reached our efforts to provide optimal 
management are likely to be frustrated in up to 36% of 
patients, as shown in our results. 
It is incumbent upon all doctors with the welfare of their 
patients at heart to devise simple, cost-effective, imaginative 
ways to try to overcome these problems. However, problem 
finding is the necessary precursor of problem solving. mJ 
CONCLUSION 
We took disease severity, the patients' social circumstances and 
available therapeutic resources into consideration in our choice 
of management approach for MG patients. In other words, we 
BDJ 
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structured our therapeutic resources to try to lessen the 
disadvantages of poverty. 
The optimal management was effective and benefited our 
patients. The main constraints on optimal management were 
socio-economic, with the result that tertiary centres were not 
fully accessible to the poorest sections of our population. Since 
socio-economic upliftment is a long-term process we will have 
to continue to find creative ways of modifying our 
management procedures to overcome this constraint. Failure to 
achieve this will perpetuate suboptimal management of 
patients. Our research project has also illustrated how clinical 
research can identify those aspects of poverty of special 
importance to the health of the population. 
We agree with Cook when he states: 'In developing countries 
defining what constitutes appropriate services and working to 
provide them should be seen as the real challenge for medicine 
in the tropics. 28 
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